Telitacicept for generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with generalized myasthenia gravis (gMG) with muscle weakness in at least one area beyond just the eyes.
- You have tested positive for AChR or MuSK antibodies in your blood.
- Your MG-ADL score (a questionnaire about daily activities) is 6 or higher, with less than half of that score coming from eye-related problems.
- Your QMG score (a measure of muscle strength) is 8 or higher, with at least 4 muscle groups scoring 2 or more points.
- You do not have other autoimmune diseases, active infections, recent thymoma (within 5 years), or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This trial tests a new type of cell therapy called STAR-T cells for adults with generalized myasthenia gravis whose symptoms are not well controlled with current treatments. The goal is to stop the immune system from attacking the body's own tissues, which might reduce muscle weakness.
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.